Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869612 | 0.86 | SIGMAR1 (0.56) | ESR1ESR2SIGMAR1PTPN1 | |
| SCHEMBL4868983 | 0.84 | SIGMAR1 (0.48) | ESR1ESR2SIGMAR1PTPN1 | |
| SCHEMBL2111349 | 0.83 | NPC1 (0.51) | ESR1ESR2SIGMAR1CES2 | |
| SCHEMBL4095524 | 0.78 | ESR1 (0.58) | ESR1ESR2CES2 | |
| SCHEMBL2113060 | 0.77 | ESR1 (0.69) | ESR1ESR2CES2 | |
| SCHEMBL2113799 | 0.76 | ESR1 (0.58) | ESR1ESR2PTPN1DEGS1 | |
| SCHEMBL2112590 | 0.76 | ESR1 (0.68) | ESR1ESR2PTPN1CES2 | |
| SCHEMBL14317832 | 0.75 | NR1H4 (0.41) | ESR1ESR2SIGMAR1PTPN1DEGS1 | |
| SCHEMBL27602615 | 0.75 | SIGMAR1 (0.47) | ESR1ESR2SIGMAR1PTPN1DEGS1 | |
| SCHEMBL865178 | 0.75 | ESR1 (0.59) | ESR1ESR2PDK1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | claimed |
| CN-101336227-A | Nuclear receptor binding agents | GTX INC (US) | 2008-12-31 | — | — | CN | claimed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| CN-102702013-B | Nuclear receptor binding agents | GTX INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| CN-102351732-B | Nuclear receptor binding agents | GTX INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| CN-101336227-A | Nuclear receptor binding agents | GTX INC (US) | 2008-12-31 | — | — | CN | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | ESR1 7/4885ESR2 3/4885SIGMAR1 996/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885SIGMAR1 496/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885SIGMAR1 496/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885SIGMAR1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.